Moonwalk Biosciences, a San Francisco and San Diego, CA-based genomic medicine company, raised $57M in Seed and Series A funding.
The rounds saw participation from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures.
The company intends to use the funds to support continued advancement of its epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.
Moonwalk Biosciences is an early-stage therapeutics company that has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.
Its innovative epigenetic editors use the cell’s natural regulation system to accurately and permanently control multiple genes in a single step, without altering the DNA sequence itself. This technique, enhanced by insights from Moonwalk’s AI-driven profiling technologies, allows the company to address multiple factors involved in complex conditions more effectively, minimizing off-target effects and toxicities while leaving the primary DNA sequence intact.
The company is launching with a veteran leadership team with deep expertise in epigenetic biology, AI, and clinical product development:
- Alex Aravanis, M.D., Ph.D., Chief Executive Officer & Co-Founder
- Arash Jamshidi, Ph.D., Co-Founder, President and Chief Technology Officer
- Justin Valley, Ph.D., Co-Founder and Chief Operating Officer
- Elaine Cheung, M.S., Chief Business Officer
- Sam Gross, Ph.D., Head of Bioinformatics & ML/AI
- Rigel Kishton, Ph.D., Head of Immunology Research
FinSMEs
05/01/2024